Using liquid biopsy from EBUS-TBNA fluid to diagnose lung cancer
Validation of Liquid Biopsy Assay of EBUS-TBNA Supernatant Fluid for Diagnosing Lung Cancer: A Feasibility Study
This study is testing if analyzing fluid from a specific lung procedure can help diagnose lung cancer in patients who are suspected to have it but have had negative test results.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Barzilai Medical Center Academic / other |
| Locations | 1 site (Ashkelon) |
| Trial ID | NCT06889467 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of analyzing the supernatant fluid from endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in diagnosing non-small cell lung cancer (NSCLC). The study focuses on patients with a high suspicion of NSCLC who have had negative EBUS-TBNA results. By utilizing next generation sequencing (NGS) on the supernatant, researchers hope to gather information about lymph node involvement in cases where traditional methods have failed. This approach could potentially reduce the need for more invasive surgical procedures.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a high suspicion of NSCLC and planned for an EBUS-TBNA procedure.
Not a fit: Patients who do not require surgical resection of thoracic lymph nodes or those in whom NSCLC is ultimately ruled out may not benefit from this study.
Why it matters
Potential benefit: If successful, this method could provide a less invasive diagnostic option for patients with suspected lung cancer.
How similar studies have performed: While the use of liquid biopsy techniques is gaining popularity, this specific approach of analyzing EBUS-TBNA supernatant for NSCLC diagnosis is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * adult (age ≥18 years) patients with high suspicion for NSCLC with thoracic lymph nodes involvement (per clinical judgement and imaging studies), planned for an EBUS-TBNA procedure * Subjects with negative EBUS-TBNA results (no evidence of lymph node involvement by tumor according to histology) who will require surgical resection of the thoracic lymph nodes will comprise the final study group Exclusion Criteria: 1. Subjects unable or not willing to provide informed consent for study participation. 2. Subjects in whom NSCLC will ultimately be ruled out. 3. Subjects who will not require surgical resection of thoracic lymph nodes, or who will not undergo such procedure in our Medical Center for any reason
Where this trial is running
Ashkelon
- Barzilai University Medical Center — Ashkelon, Israel (Recruiting)
Study contacts
- Study coordinator: Ori Wand, MD
- Email: oriw@bmc.gov.il
- Phone: 97285564421
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.